DSP 2230

Drug Profile

DSP 2230

Alternative Names: DSP-2230

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Sumitomo Dainippon Pharma
  • Class Analgesics
  • Mechanism of Action Nav1.7-voltage-gated-sodium-channel-inhibitors; Nav1.8 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Neuropathic pain

Most Recent Events

  • 27 Oct 2016 Phase-I clinical trials in Neuropathic pain in Japan (PO) (Sumitomo Dainippon Pharma pipeline, October 2016)
  • 14 Oct 2016 DSP 2230 is still in phase I development in Neuropathic pain on USA and the United Kingdom (Sunovian Pharmaceuticals pipeline, October 2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Neuropathic-pain(In volunteers) in United Kingdom (PO, Suspension)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top